Ornim Medical

The core of Ornim Medical's product line is the proprietary, patented UTLight™ technology, which combines ultrasound and light to non-invasively measure regional blood flow and oxygen saturation. This technology differentiates itself from other Near-Infrared Spectroscopy (NIRS) methods by analyzing the light speckle signal, not just the intensity of light. The company holds a portfolio of 13 granted patents for this technology. Its primary products are the CerOx™ and c-FLOW™ monitors, which provide real-time, non-invasive measurements of cerebral blood flow (CBF) and oxygenation, targeting critical care settings like intensive care units and operating rooms. These devices are designed to assist physicians in managing patient care where tissue perfusion is critical, aiming to improve outcomes and reduce healthcare costs. The CerOx™ monitor was cleared by the FDA in 2012 and has received CE marking. The c-FLOW™ device, a more focused version measuring only blood flow, received FDA clearance in 2015.

Ornim Medical serves hospitals and clinical settings, particularly in neurology, anesthesiology, and critical care. The company's business model revolves around the sale of these monitoring devices and likely associated consumables. It has raised significant funding over the years, including a $20 million round in 2015 from investors such as OrbiMed, GE Ventures, and the Jesselson family's investment arm, bringing its total funding to approximately $37 million by that time.